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usefulness in guiding initial antifungal therapy was approximately
70%.
Conclusion: Alternate day determination of BG concentrations in
pts with PFN is a useful adjunct in identifying those who develop
IM, when used as part of an overall clinical and radiological evalu-
ation strategy. Pts with transient elevation of BG usually had ente-
rocolitis and thus may have low-burden fungemia of gut origin.
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The Prevalence and Management of Anaemia Amongst
Patients With Cancer in Cameroon
David Nkengafac, Fidelis Gira, Matina Susue, Caroline Tinato,
Relindis Ajem. Institute for Biomedical Research, South West
Province, Buea, Cameroon
Background: Anaemia is one of the most dreaded complications
among patients with malignant pathologies. Its causes can be var-
ied and whatever its severity, the impact on the quality of life of
the patient remains essential. Despite this complication in cancer
patients, limited studies have been conducted in this field and so
research data in the literature concerning anaemia are very lim-
ited. This study was therefore conducted to determine the preva-
lence and the management of anaemia amongst patients with ma-
lignant diseases.
Methods: A national survey was conducted between February 2006
and March 2007. This observational multicentric study was con-
ducted with 150 experts practicing in all the major health institu-
tions or units treating patients with solid tumours and/or malignant
haematological diseases in Cameroon. Control over one day stan-
dard of consultation for each questioned expert, 534 patients were
enrolled, including 335 (62.7%) patient with solid tumour and 199
(37.3%) patient with malignant haematological disease.
Results: The median age was 48 years (range: 11- 82 years) includ-
ing 162 men (30%) and 372 women (70%). At enrollment, the me-
dian level of haemoglobin (Hb) was 10.3 g/dl (range: 4.7-17.3 g/dl)
and 38% of patient had a level of Hb < 11 g/dl. Anaemia was found
in all the cancer localizations and whatever the stage or the ther-
apeutic status of the disease. About 3/4 of the anaemic patients
received treatment by erythropoiesis stimulating agent (ESA) and
approximately 24% of them did not receive any specific treatment
for the anaemia. The median level of Hb at the introduction of the
ESA was 9.2 g/dl.
Conclusion: Our results show an improvement in the management
of anaemia and the use of the ESA in patients with various cancers.
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Fungal Strains Isolated from Blood of Heamatological
Patients Hospitalized in Clinical Hospital of Medical
University of Warsaw in 2007 – Etiological Agents and their
Susceptibility
Ewa Swoboda-Kopec, Irena Netsvyetayeva, Beata Sulik-Tyszka,
Ewa Stelmach, Magdalena Sikora, Sylwia Blachnio,
Dariusz Kawecki, Miroslaw Luczak. Dept. of Medical Microbiology
Medical University of Warsaw, Poland
Objective: Identification and susceptibility tests on strains iso-
lated from blood samples of patients hospitalized in Department
of Haematology in 2007.
Materials and Methods: From January to the end of December 2007
in Mycology Laboratory the 427 positive mycological cultures from
clinical samples of patients hospitalized in Department of Haema-
tology were identified. Fifteen (3,5%) of all specimens were the
blood positive samples. The clinical material was examined accord-
ing to the standard mycological procedures. The isolated strains
were incubated on Sabouraud medium plates with addition of gen-
tamicin and chloramphenicol (Becton Dickinson). The identifica-
tion of the isolates was performed on CHROMagar Candida medium
and automatic test of ID32 C (bioMerieux). The susceptibility tests
for antifungal agents: Amphotericin B, Itraconazole, Fluconazole,
Voriconazole, Caspofungin and Posaconazole, was done using E-
tests (AB Biodisk).
Results: From the whole number of 427 samples from Department
of Haematology, the positive blood samples were 3.5% - 15. The
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most common isolates were yeast like fungi- 14 strains (99%). The
dominant strains from Candida genus were C. glabrata 4 (28.5%),
C. krusei 4 (28.5%), C. albicans 2 (14.3%), C. tropicalis 1 (7.2%),
C. parapsilosis 1 (7.2%). Other fungal strains: Cryptococcus neo-
formans isolated in 2 cases (14.3%) and Aspergillus fumigatus. 1
strain- 6.7% out of the total number of cultures. The susceptibil-
ity of isolates for Amphotericine B and Voriconazole was 100%. In
13 strains which were tested for Itraconazole, 6 (46%) were re-
sistant, the 16.7% of analyzed spesies were Flukonazole resistant.
100% of C. glabrata isolates were susceptible for Caspofungin and
Posaconazole.
Conclusions: The performed analyses indicated that yeast like
fungi had the highest contribution in fungemias (99%). The main
etiological factors of fungemia in immunodeficient patients were
non-albicans species 66.7% 3. The dominant species from Can-
dida genus with increased resistance for antifungal agents were
C. glabrata 33.3% and C.krusei 33.3%. The most efficient antifun-
gal agents were in vitro Amphotericin B and Voriconazole.
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A Case of Pulmonary Angioinvasive Zygomycosis in a
Patient with Acute Promyelocytic Leukemia successfully
treated with Surgical Resection and Posaconazole
Julio Mendez. Mayo Clinic Jacksonville, Division of Infectious
Diseases, Jacksonville, Florida, USA
31-year-old African American male patient previously healthy and
a retired professional football player presented to his primary care
physician on early August of 2007 complaining of cough, and ini-
tially treated for a suspected upper respiratory infection with cef-
podoxime and doxycycline without any improvement. On August
20, 2007, he developed hemoptysis and was found to have ane-
mia (8.2 g/dL), thrombocytopenia (23,000/mm3) and leukocytosis
(14.500/mm3) with 50% blasts. A bone marrow biopsy on August
21, 2007 was consistent with Acute Promyelocytic Leukemia (APL)
and started induction chemotherapy on August 24, 2007 with ATRA,
Idarubicin, and Dexamethasone until August 30, 2007 when Idaru-
bicin and Dexamethasone were discontinued and was kept on ATRA.
He became neutropenic on August 27, 2007 and on September 9,
2007 developed fever associated with a right middle lobe consoli-
dation and a right pleural effusion and thoracentesis cultures were
negative. He remained neutropenic until September 17, 2007 and
during this time received broad spectrum antibiotics and antifun-
gals including Caspofungin from August 24, 2007 to September 6,
2007, Voriconazole from September 6, to September 10, 2007 and
Ambisome from September 10, 2007 until October 9, 2007. On
September 21, 2007 and due to the progression of the infiltrate,
he had a bronchoscopy and a transbronchial biopsy was consis-
tent with Angioinvasive Zygomycosis and was kept on intravenous
Ambisome and Posaconazole was added. On October 1, 2007, he
underwent a right exploratory thoracotomy with decortication of
the right lower lobe and partial parietal pleurectomy and right
middle lobectomy and the pathologic report showed Angioinvasive
Zygomycosis, however, the fungal cultures were negative. He re-
mained on intravenous Ambisome and Posaconazole and fourteen
days later was dismissed home on Posaconazole with the intention
to continue this agent while on therapy for the APL and to extend
the treatment for one additional year post-remission. PCRs for APL
in peripheral blood have been negative since October 15, 2007.
Conclusion: He is currently on therapy for the APL with ATRA,
Methotrexate, and 6-Mercaptopurine and the plan is to extend
this regimen for two years. He was re-evaluated on February 5,
2008 and was asymptomatic and follow-up chest x-rays have con-
tinued to show signs of resolution and is now only consistent with
post-operative changes. He has continued to tolerate Posaconazole
well.
65
Invasive Zygomycoses in a Tertiary Hhaematooncological
Centre in the Czech Republic
Michal Kouba1, Vít Campr2, David Pohlreich1, Petr Cetkovský1.
1Institute of Haematology and Blood Transfusion, Clinical
Department, Prague, Czech Republic; 2Institute of Pathology and
Molecular Medicine of the 2nd Medical Faculty of the Charles
University, University Hospital Motol, Prague, Czech Republic
Background: Infections by Zygomycetes (class Zygomycetes, most
infections by fungi of the Mucorales order) are rare emerging
mould infections found almost exclusively among immunocompro-
mised patients (malignant diseases, after haematopietic stem cell
transplantation (HSCT) or solid organ transplantation, neutrope-
nia, iron overload, diabetes mellitus, drug addiction ...). In the
last decades the number of referred cases in English written lit-
erature increased. The outcome of treatment is slowly improving
due to aggressive surgical treatment together with modern antimy-
cotic treatment. In spite of that the mortality of pulmonary form
remains over 80%.
Materials: We summarized the invasive infections by Zygomycetes
in a 33 bed (21 standard beds, 8 intensive care beds, 4 transplant
beds) tertiary hematooncological centre in Prague, Czech Republic.
Methods: A prospective monitoring of mould infections in the time
period 1/2003-12/2007 was used and we choose only the proven
cases (according to EORTC-MSG criteria).
Results: There were two clusters of infections by Zygomycetes in
60 months – 4 proven cases in 1-4/2003, all caused by Rhizomucor
pusillus, which had been identified in hospital environment be-
fore the clinical cases appeared. 2 proven cases 12/2005-1/2006
were identified by histology without further specification by cul-
ture. Four of 6 patients were after HSCT and 2 after therapy for
acute leukemias. Five of 6 patients developed pulmonary form,
one of HSCT patients developed disseminated form. 4 patients died
from the progression of mycosis, one died from the relapsing ma-
lignancy, one patient lives without any sign of fungal infection.
Conclusions: The aforementioned cases support the evidence of
poor outcome of zygomycoses in haematooncology patients. The
predominance of pulmonary form and high mortality in this patient
group is in concordance with literature. The clustering of cases
to two time periods and identification of Zygomycetes in hospital
environment prior to the first period support the idea of higher
vigilance and/or preventive measures (change in antimycotic pol-
icy or temporary closure of the unit) when these extremely dan-
gerous fungi are found in the environment of immunocompromised
patient.
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Immunocompromised Patients with Possible Sphenoid Sinus
Aspergilloma the Role of Detection of Aspergillus Antigen
Galactomannan
Polyzo Kazila1, Eleni Kaitsa1, Soultana Kostopoulou1,
Evaggelos Antonakis1, Vasiliki Gastari2, Eirini Katodritou2,
Konstantinos Zervas2. 1Laboratory of Microbiology, “Theagenio"
Cancer Hospital, Thessaloniki Greece; 2Haematology Clinic,
“Theagenio" Cancer Hospital, Thessaloniki Greece
Background: The invasive infections from Aspergillus are a major
cause of morbidity and mortality in immunocompromised patients.
The diagnosis is based on the histological tests and the growth of
the fungus in a tissue culture, after a dangerous and therefore
avoided in neutropenic patient' s biopsy. The combination of the
detection of Aspergillus antigen Galactomannan (GM) in serum and
X-ray findings is considered to be an indication equivalent to a pos-
itive biopsy sample.
